Five-year survival from pediatric cancer rises to nearly 90% overall, but disparities by race and cancer type remain

by Ann & Robert H. Lurie Children's Hospital of Chicago

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

Nearly nine in 10 young people with cancer were alive five years after diagnosis by 2017—up from six in 10 in 1975, according to the first comprehensive update of U.S. childhood cancer survival statistics in over a decade published in the Journal of the National Cancer Institute.

But this immense progress did not reach everyone equally. Some cancers, like certain leukemias and bone/soft tissue cancers (called sarcomas), have improved much less than others. Also, Black children and teenagers had worse survival across most cancer types.

"Our study shows that childhood cancer is one of modern medicine's greatest success stories," said lead author Lindsay Schwartz, M.D., M.S., a pediatric oncologist at Ann & Robert H. Lurie Children's Hospital of Chicago and assistant professor of pediatrics at Northwestern University Feinberg School of Medicine.

"Molecularly targeted agents and immunotherapies have increasingly been integrated into treatment and may have improved survival among young patients not cured with conventional chemotherapy while reducing late mortality from toxic treatments. Survival gains also likely have been driven by advances in precision diagnostics, risk stratification and inclusive cooperative group trials. Our findings, however, also point to where children and families still need us to do better."

Schwartz and colleagues examined registry data covering more than 100,000 children and teenagers (ages 0–19 years) diagnosed with cancer in the U.S. between 1975 and 2022. They used data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) 8 and 17 databases. Researchers evaluated trends in five-year overall survival among different sociodemographic groups.

From 2000 to 2017 for all cancer types combined, five-year overall survival was 88% for non-Hispanic white patients, 84.5% for Hispanic patients, 85.6% for patients of other races and ethnicities and 80.8% for non-Hispanic Black patients.

Disparities in survival also emerged by cancer type. Whereas five-year survival for acute lymphoblastic leukemia (ALL), the most common childhood cancer, rose from 43% in 1975 to 95% in 2017, survival for acute myeloid leukemia (AML) is still around 72%, and for sarcomas around 74%.

"For AML, sarcomas and high-risk neuroblastoma, children still need new and better treatments, and research on them should be a priority," said Schwartz.

"We still need to learn why survival gaps persist," she said. "The reasons for these gaps are probably a mix of factors—access to care, insurance, where families live, how the cancer itself behaves biologically and treatment side effects. Learning which of these matters most is key to making sure every child benefits from medical advances."

Survival at five years was also not the whole story—some survivors, especially young people treated for Hodgkin lymphoma decades ago, die at higher rates 20–30 years after their cancer was cured, often from long-term effects of treatment. People treated for Hodgkin lymphoma in the 1970s and early 1980s had 87% survival at five years post-diagnosis, but only 63% at 30 years post-diagnosis.

"Families and doctors should know that lifelong follow-up care after cancer matters, including screening for second cancers and heart problems," stressed Schwartz. "Collectively, our findings underscore the need for continued progress not only in developing effective and less toxic therapies but also in ensuring these advances are accessible to every child and adolescent with cancer."

Publication details

Lindsay F Schwartz et al., Advances and disparities in survival of childhood and adolescent cancers, JNCI: Journal of the National Cancer Institute (2026). DOI: 10.1093/jnci/djag155

Journal information: Journal of the National Cancer Institute

Key medical concepts

Cancer in ChildrenAcute Myeloid LeukemiaSarcomaAcute Lymphocytic Leukemia

Clinical categories

PediatricsOncologyChildren's healthCommon illnesses & Prevention Provided by Ann & Robert H. Lurie Children's Hospital of Chicago Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Five-year survival from pediatric cancer rises to nearly 90% overall, but disparities by race and cancer type remain (2026, November 11) retrieved 11 November 2026 from https://medicalxpress.com/news/2026-11-year-survival-pediatric-cancer-disparities.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.